CAR-T Fatalities Prompt Pauses at Novartis and BMS
TL;DR Summary
Three patients died in Novartis's CD19-directed CAR-T trials due to a dangerous immune reaction, prompting a halt to those programs, with Bristol Myers Squibb pausing a similar therapy as well.
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
0 min
vs 1 min read
Condensed
65%
85 → 30 words
Want the full story? Read the original article
Read on Endpoints News